BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Duvie (Lobeglitazone) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Duvie (Lobeglitazone)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07108985-293@assetmemo.bio
DTSTAMP:20261121T010124Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Duvie (Lobeglitazone): Phase 4 readout est. (NCT07108985)
DESCRIPTION:Duvie (Lobeglitazone)\, phase 4\, Type 2 Diabetes.\nStudy: Effe
 ct of Add-on SGLT2i\, TZD\, or Combination Therapy in Type 2 Diabetes Pati
 ents on DPP4 Inhibitors\nEstimated primary completion: 1 September 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/lobeglitazone#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07108985
URL:https://assetmemo.bio/drug/lobeglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
